Investing in MegaTrends
Megatrends are large-scale, long-term trends that significantly shape the future of society, economy, and technology. These trends include digital transformation, globalization, climate change, aging populations, urbanization, and the push for sustainability. Digital transformation drives innovation and disrupts industries, while globalization increases economic and cultural interconnectedness. Climate change and sustainability efforts reshape industries and policies, while aging populations challenge healthcare and social systems. Urbanization shifts demographics and infrastructure needs.
These megatrends interact and influence each other, creating both opportunities and challenges. Understanding them is essential for strategic planning, policy-making, and adapting to the future.
Our easy-to-use guides will take you through the options available to you in order to gain exposure in your portfolio to these important trends.
How to invest in the latest MegaTrends
There are a number of different routes towards investing in the growth of these MegaTrends. Exchange-Traded Funds (“ETFs”) are a great place to start and there is a range of options available for investors within each sector. The advantage of these is that they can capture a lot of the long-term growth across these megatrends, without the risk of investing in single stocks.
For those who are meaningfully more risk tolerant, individual stock picking remains an option. Some safer (but severely more diluted) options include cutting edge larger firms with established business that are already reaping the rewards of exposure to a megatrend sector. Investors with a higher tolerance for risk might look for a unicorn – that’s a small business that could reap significant rewards in the future due to its exposure to the megatrend. However, these unicorn’s, as the name suggests, are hard to find, and for every success story, there will be many failures.
Take a look at our reports below for some investing ideas.
Advertisement
Sign up for a weekly round up of our best investment ideas, insight and tips.
Has Michael Burry got it right about AI sector earnings?
It was inevitable that Big Short legend Michael Burry would eventually take aim at the great secular religion of our time.
The AI concentration risk nobody wants to discuss
It seems that nobody wants to discuss the extraordinary concentration of market value in a narrow cohort of AI-focused technology companies.
Artificial Intelligence: boom, bust or just beginning?
The torrent of money pouring into artificial intelligence (AI) has invited comparisons with the dotcom boom.
Seeing Machines lands breakthrough North American deal
Seeing Machines has secured a significant order to supply its Guardian system to the distribution fleet of a major US multinational.
The quant crunch: finance’s AI skills gap widens
A survey has found that less than 10% of industry professionals believe new graduates possess the AI skills deemed essential for success.
MedPal AI wins NHS pharmacy approval
Transfer of pharmacy contract gives MedPal’s subsidiary the right to operate a Distance Selling Pharmacy under NHS regulation.
Asia’s Top Five Mid-Cap Stocks To Watch In Q4
We reviewed the Asian mid cap market to identify what look like some of the hottest bets in this fast-growing region.
What we learned from last week’s Big Tech earnings marathon
This earnings season has laid bare a split within Big Tech that could define the next phase of the artificial intelligence boom.
Pila Pharma share issue for obesity drug research is massively oversubscribed
The issue was oversubscribed by 293.5%, underscoring strong investor appetite despite a challenging environment for life sciences funding.
Rosslyn narrows losses as AI tools begin to lift turnaround
Chief executive Paul Watts said Rosslyn had reached a “pivotal moment” after a period of restructuring and investment in new technology.
Beximco’s plans for affordable generic cystic fibrosis drug
The initiative is a challenge to Vertex Pharmaceuticals’ monopoly over Trikafta, a therapy that has revolutionised care for cystic fibrosis.
Pictet brings trio of active ETFs to the US market
The move represents a strategic foray into one of the fastest-growing areas of asset management, where active ETFs have gained traction.
Oxford BioDynamics has important role in future cancer screening says report
Oxford BioDynamics has welcomed a new report that calls for the introduction of targeted prostate cancer screening in the UK.
China innovation: Can income investors participate?
The overall income yield of the Chinese market, at 2.4%, is still relatively low but there is scope to pay higher dividends
IP Group eyes potential royalties from obesity drug
IP Group has highlighted the potential for future royalty revenues tied to breakthrough obesity drug candidates under development by Metsera.
Is the AI sector now trading in bubble territory?
Unlike the dot-com mania of the late 1990s, the current enthusiasm rests on tangible earnings and surging capital expenditure.
Energy developer Fermi in concurrent IPO on LSE and NASDAQ
US energy developer Fermi has become the first company to complete a concurrent dual listing on both Nasdaq and the London Stock Exchange.
UK retail investors embrace AI as adoption surges 45% in a year
AI is no longer just the preserve of Silicon Valley or Wall Street quants. It is now firmly in the hands of everyday investors.
Why tariffs could ruin the pharma sector’s year
Analysts believe that US tariffs on high-value medicines will ripple through every part of the global health economy
What is going to be the dominant investment theme in 2026?
Which sector is poised to continue to dominate global markets in 2026? We get the download from a leading UK wealth manager.
Arecor Therapeutics extends cash runway with US partnerships
Arecor has bolstered its balance sheet and sharpened its clinical focus, signing two US partnerships that will accelerate its drug pipeline.
N4 Pharma achieves proof of targeted RNA delivery in lung cancer cells
N4 Pharma reports a breakthrough for its proprietary Nuvec delivery system in its collaboration with US non-profit research institute SRI
AstraZeneca’s Koselugo looks set for EU approval
European Medicines Agency's positive response follows results from the KOMET trial and could soon open market for successful treatment.
Great Portland Estates lands AI tenant in London tech race
Great Portland Estates has reinforced its role as a landlord of choice for artificial intelligence businesses.
WisdomTree launches quantum computing ETF as sector nears commercial breakthrough
WisdomTree has rolled out a new ETF targeting quantum computing, giving investors exposure to one of technology’s most hyped frontiers.
iZafe’s recurring revenues are up as European expansion gathers pace
iZafe has continued its transition away from hardware sales and scaled up its Dosell medication robot across Europe.
NVIDIA: From hyper growth to high growth, but is it enough?
NVIDIA's latest set of results have some important lessons for investors interested in the artificial intelligence boom market.
Aptamer launches biomarker discovery service to expand revenue base
Aptamer Group has unveiled a new biomarker discovery service as part of efforts to broaden its revenue streams.
NVIDIA’s earnings may outweigh the Fed’s impact on S&P 500 this week
The fate of Wall Street may rest less on Powell’s dovish hints and the next inflation print than on the results of a single company.
Bunzl bolsters global footprint with new acquisitions
Bunzl has pressed ahead with its acquisitive growth strategy, announcing two further purchases and completing two previously disclosed deals.
Inspiration Healthcare posts record half-year revenues as turnaround gathers pace
Inspiration reported record half-year revenues of £24m for the six months to 31 July 2025, a 41% increase on the previous year.
Precious metals investors are going it alone
The vast majority of precious metals investors trust and rely on their own thinking and judgement for their investment decisions.
EDX Medical to roll out rapid pneumonia test for NHS
A new UK-developed diagnostic test promises to transform the detection and treatment of pneumonia in intensive care units.
Share Tip: an innovative FTSE 250 business with strong growth potential
Excitement is beginning to build around this FTSE 250 business and its innovative developments in farm animal genetics
AI market on brink of “seismic shift”, say investors
Institutional investors and wealth managers believe that the artificial intelligence (AI) market is on the brink of a seismic shift.
The AI Bubble: How to pick the winners before it bursts
AI chatbot companies are valued as if their future profits will be very large, but the market for AI chatbots is too competitive.
Hikma Pharmaceuticals: a quality compounder waiting for a catalyst
Hikma Pharmaceuticals is grounded in the consistency of a disciplined compounder, combining operational prowess and defensive appeal
What are the top US value stocks to watch in Q3?
This week we run our value metrics over the US mid and large cap sectors to see which stocks are looking undervalued.
Switzerland is emerging as Europe’s Deep Tech powerhouse
Switzerland has positioned itself as arguably the European leader across a number of Deep Tech innovation silos.
CFTC will seek higher penalties for AI-driven market manipulation
CFTC Commissioner Kristin Johnson says AI is a double-edged sword, but can also help with regulation of markets.
Can capAI’s alliance with R42 take shares to new levels?
London-listed capAI has just announced a strategic alliance with R42, a US based incubator focused on early stage investment.
GenIP shares up 21% on new analytics service and major client
GenIP announced the launch of a new AI-powered product and its first client for the new product, a Big Four accountancy firm.
The top 6 questions Pro Investors are asking AI
What are professional investors asking AI about during the current market turbulence and how will that define Wall Street in the future?
BridgeWise to bring AI stock research services to UAE market
The AI-powered investment intelligence platform has entered the Gulf region after securing an operational license from the DIFC.
IPO Radar: VERAXA, CATL and Zopa
VERAXA plans major RTO in the US, Congress gets shirty with banks over CATL, and Zopa CEO pauses US IPO plans.
Don’t give up on NVIDIA yet, says fund manager
Leading investor in robotics and AI stocks says tariffs will not sink NVIDIA but that investors need to "fasten their seat belts".
IPO Radar: Newsmax, Aspargo Labs and Chime Financial
In IPO news this week, we look at Trump endorsed Newsmax, pharma play Aspargo Labs and US mobile banking provider, Chime Financial
Pila Pharma: Obesity drug R&D could make it takeover target
Within a few years, Pila Pharma aims to be acquired by or partner with an industry player like Novo Nordisk.
What’s dragging down the NVIDIA share price this week?
One of the main factors is concern over energy efficiency regulations in China, which could affect the sale of NVIDIA's AI chips.
Wellnex IPO: A shot in the arm for struggling UK junior market
Wellnex Life IPOs on AIM, raising £5.2m to pay off debt, convertible notes and invest in product development and international expansion.
